Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07011732 · ClinicalTrials.gov registry record · Phase 3

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

A Phase 3 study of Alzheimer Disease, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 3
Development phase
352
Enrollment target
20
Study locations

NCT07011732: Recruiting Phase 3 study of Alzheimer Disease, sponsored by Bristol-Myers Squibb.

NCT07011732 is a Phase 3 study of Alzheimer Disease that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 352 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07011732, a Phase 3 study of Alzheimer Disease, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 3
Development phase
352 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

Conditions Studied

Alzheimer Disease

Interventions

  • DRUG Placebo
  • DRUG Xanomeline/Trospium Chloride Capsule
  • DRUG Xanomeline Enteric Capsule

Study Locations (20)

Florida

  • Local Institution - 1622 - Maitland
  • Local Institution - 1631 - Maitland
  • Local Institution - 1602 - Miami
  • Local Institution - 1618 - Miami
  • Hope Research Network - Miami - Miami
  • Nuovida Research Center - Miami
  • Local Institution - 1608 - Ocala
  • Combined Research Orlando (CRO) - Orlando
  • Progressive Medical Research - Port Orange

California

  • Advanced Research Center (ARC) - Anaheim - Anaheim
  • Kaizen Brain Center - La Jolla
  • The Neurology Group - Pomona
  • Torrance Clinical Research - Torrance
  • Sunwise Clinical Research - Walnut Creek

Arizona

  • Imaging Endpoints - Scottsdale

Colorado

  • Local Institution - 1630 - Colorado Springs

Georgia

  • Local Institution - 1661 - Savannah

Louisiana

  • Local Institution - 1655 - Marrero

Maryland

  • CBH Health - Gaithersburg

Massachusetts

  • Local Institution - 1663 - Foxborough

Trial Details

FieldValue
Enrollment Target 352 participants
Start Date 2025-07-10
Est. Completion 2028-12-08
Phase Phase 3
Bristol-Myers Squibb

1,025 total trials

What NCT07011732 shows while recruiting

NCT07011732 is an interventional study that assigns participants to a tested intervention. The registered 352 participants enrollment target is mid-sized for trials with a published cap, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT07011732 names 20 study sites across 8 states, led by Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT07011732 about?

NCT07011732 is a clinical study titled "A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)". The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

What is the current status of trial NCT07011732?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 352 participants. The study started on 2025-07-10. Estimated completion is 2028-12-08.

What conditions does trial NCT07011732 study?

This clinical trial studies the following conditions: Alzheimer Disease.

What interventions are being tested in trial NCT07011732?

The interventions under investigation include: Placebo (DRUG), Xanomeline/Trospium Chloride Capsule (DRUG), Xanomeline Enteric Capsule (DRUG).

Who is sponsoring clinical trial NCT07011732?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07011732 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07011732's enrollment target sits among peer trials

352 73rd of 306 higher than 233 of 306 other Alzheimer Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05811936 · 352 participants · NA

    The SNAP Tool for Head and Neck Cancer Survivor-Caregiver Dyads

  • NCT06258941 · 352 participants · Phase 1

    Classroom Break, Cognition, and Fitness in Elementary School Children

  • NCT06269081 · 352 participants · NA

    Testing Two Interventions to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV

  • NCT06337292 · 352 participants · Phase 3

    Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07011732

Source: ClinicalTrials.gov NCT07011732, the US trial registry maintained by the National Library of Medicine. NCT07011732 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.